These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28468085)

  • 21. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.
    Cremers EM; Westers TM; Alhan C; Cali C; Visser-Wisselaar HA; Chitu DA; van der Velden VH; Te Marvelde JG; Klein SK; Muus P; Vellenga E; de Greef GE; Legdeur MC; Wijermans PW; Stevens-Kroef MJ; Silva-Coelho PD; Jansen JH; Ossenkoppele GJ; van de Loosdrecht AA;
    Haematologica; 2017 Feb; 102(2):320-326. PubMed ID: 27658438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France).
    Maynadié M; Girodon F; Manivet-Janoray I; Mounier M; Mugneret F; Bailly F; Favre B; Caillot D; Petrella T; Flesch M; Carli PM
    Haematologica; 2011 Jan; 96(1):55-61. PubMed ID: 20971817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.
    Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Ardanaz MT; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
    Mod Pathol; 2016 Dec; 29(12):1541-1551. PubMed ID: 27562492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
    Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
    Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes.
    Zuo Z; Maiti S; Hu S; Loghavi S; Calin GA; Garcia-Manero G; Kantarjian HM; Medeiros LJ; Cooper LJ; Bueso-Ramos CE
    Mod Pathol; 2015 Mar; 28(3):373-82. PubMed ID: 25216221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems.
    Fu B; Jaso JM; Sargent RL; Goswami M; Verstovsek S; Medeiros LJ; Wang SA
    Mod Pathol; 2014 May; 27(5):681-9. PubMed ID: 24186132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
    Fernandez-Mercado M; Burns A; Pellagatti A; Giagounidis A; Germing U; Agirre X; Prosper F; Aul C; Killick S; Wainscoat JS; Schuh A; Boultwood J
    Haematologica; 2013 Dec; 98(12):1856-64. PubMed ID: 23831921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.
    Kiladjian JJ; Visentin G; Viey E; Chevret S; Eclache V; Stirnemann J; Bourhis JH; Chouaib S; Fenaux P; Caignard A
    Haematologica; 2008 Mar; 93(3):381-9. PubMed ID: 18268282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes.
    Yoshida A; Zokumasu K; Wano Y; Yamauchi T; Imamura S; Takagi K; Kishi S; Urasaki Y; Tohyama K; Ueda T
    Haematologica; 2012 Sep; 97(9):1372-9. PubMed ID: 22419576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells.
    Pu JJ; Hu R; Mukhina GL; Carraway HE; McDevitt MA; Brodsky RA
    Haematologica; 2012 Aug; 97(8):1225-33. PubMed ID: 22315493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.
    van de Loosdrecht AA; Alhan C; Béné MC; Della Porta MG; Dräger AM; Feuillard J; Font P; Germing U; Haase D; Homburg CH; Ireland R; Jansen JH; Kern W; Malcovati L; Te Marvelde JG; Mufti GJ; Ogata K; Orfao A; Ossenkoppele GJ; Porwit A; Preijers FW; Richards SJ; Schuurhuis GJ; Subirá D; Valent P; van der Velden VH; Vyas P; Westra AH; de Witte TM; Wells DA; Loken MR; Westers TM
    Haematologica; 2009 Aug; 94(8):1124-34. PubMed ID: 19546437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies.
    Kelaidi C; Stamatoullas A; Beyne-Rauzy O; Raffoux E; Quesnel B; Guerci A; Dreyfus F; Brechignac S; Berthou C; Prebet T; Hicheri Y; Hacini M; Delaunay J; Gourin MP; Camo JM; Zerazhi H; Taksin AL; Legros L; Choufi B; Fenaux P;
    Haematologica; 2010 Jun; 95(6):892-9. PubMed ID: 20015890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
    Bacher U; Haferlach C; Alpermann T; Kern W; Schnittger S; Haferlach T
    Haematologica; 2011 Sep; 96(9):1284-92. PubMed ID: 21606170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel RUNX1 mutation with ANKRD26 dysregulation is related to thrombocytopenia in a sporadic form of myelodysplastic syndrome.
    Ferrari S; Regazzo D; Omenetto E; Scaroni C; Semenzato G; Fabris F; Vianello F
    Aging Clin Exp Res; 2021 Jul; 33(7):1987-1992. PubMed ID: 32944898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.
    Basiorka AA; McGraw KL; Abbas-Aghababazadeh F; McLemore AF; Vincelette ND; Ward GA; Eksioglu EA; Sallman DA; Ali NA; Padron E; Pinilla-Ibarz J; Komrokji R; Masala E; Santini V; Kosmider O; Fontenay M; Fenaux P; Sokol L; Wei S; Fridley B; List AF
    Lancet Haematol; 2018 Sep; 5(9):e393-e402. PubMed ID: 30072146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An association of polymyalgia rheumatica with myelodysplastic syndromes.
    Kohli M; Bennett RM
    J Rheumatol; 1994 Jul; 21(7):1357-9. PubMed ID: 7966085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When to treat myelodysplastic syndromes.
    Akhtari M
    Oncology (Williston Park); 2011 May; 25(6):480-6. PubMed ID: 21717901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
    Loiseau C; Ali A; Itzykson R
    Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [How I treat myelodysplastic syndromes with allogeneic hematopoietic stem cell transplantation].
    Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):10-14. PubMed ID: 33677862
    [No Abstract]   [Full Text] [Related]  

  • 40. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Bardet V; Wagner-Ballon O; Guy J; Morvan C; Debord C; Trimoreau F; Benayoun E; Chapuis N; Freynet N; Rossi C; Mathis S; Gourin MP; Toma A; Béné MC; Feuillard J; Guérin E; ;
    Haematologica; 2015 Apr; 100(4):472-8. PubMed ID: 25637056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.